HDM2005
Phase 2Small molecule
HDM2005 is one of 162 small molecule programs targeting Mantle Cell Lymphoma. It is currently in Phase 2.
4
Indications
4
Total Trials
4
Active Trials
161
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
401 competitors in Lymphoma
#DrugCompanyPhaseTrials
1HDM2005
HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
Phase 2
Zofran
NovartisPreclinical
Cabenuva
GSKPreclinical
Norvir
AbbViePreclinical
Emend
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Kenalog
BBausch Health Americas, Inc.
Preclinical
Nuvigil
NNuvo Research GmbH
Preclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
Decadron
QQuince Therapeutics S.p.A.
Preclinical
Solu-Medrol
MMassachusetts Eye and Ear Infirmary
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Diffuse Large B-Cell Lymphoma1 trial
Lymphoma1 trial
Mantle Cell Lymphoma1 trial
A Phase Ib/III Clinical Trial to Evaluate HDM2005 in Combination Therapy for Patients With Relapsed/Refractory Mantle Cell Lymphoma
Not yet recruiting·HHangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.·Phase 1·NCT07697339·40 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for HDM2005. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details